PHARMACOECONOMICS OF THE NEW ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA-Reference-Cited by-同舟云学术

PHARMACOECONOMICS OF THE NEW ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA

Published:1998-03 Issue:1 Volume:21 Page:181-202
ISSN:0193-953X
Container-title:Psychiatric Clinics of North America
language:en
Short-container-title:Psychiatric Clinics of North America

Author:

Zito Julie Magno

Publisher

Elsevier BV

Subject

Psychiatry and Mental health

Reference66 articles.

1. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study;Addington;Clin Therapeutics,1993

2. Cost effectiveness of clozapine;Aitchison;Br J Psychiatry,1997

3. Reduction of health care resources utilization and cost following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy;Albright;Clin Pharmacoeconomics,1996

4. Anonymous: Section 505 (b) of the Federal Food, Drug and Cosmetic Act 21 USC 321 et seq 505 (b)1995 [abstract], GPO, Washington, DC

5. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association;Anonymous;Am J Psychiatry,1997

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haloperidol dose for the acute phase of schizophrenia;Cochrane Database of Systematic Reviews;2013-08-28

2. Long-Acting Injectable Risperidone for the Treatment of Schizophrenia;Drugs;2007

3. Pharmakoökonomie;Praktische Psychopharmakotherapie;2006

4. Risperidone: a review;Expert Opinion on Pharmacotherapy;2005-05

5. Results of a naturalistic study of treatment options: Switching atypical antipsychotic drugs or augmenting with valproate;Clinical Therapeutics;2004-06